| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
87,420,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Centessa Pharmaceuticals is a pharmaceutical company that develops and delivers life-altering and life-enhancing medicines to patients. Co.'s product pipeline includes: Lixivaptan, a vasopressin V2 receptor small molecule inhibitor; SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody for the treatment of cutaneous squamous cell carcinoma and for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin for the treatment of alpha-1-antitrypsin deficiency.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$46,284 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
51,160 |
55,427 |
107,411 |
368,796 |
| Total Sell Value |
$607,960 |
$642,534 |
$943,036 |
$2,119,530 |
| Total People Sold |
1 |
2 |
4 |
10 |
| Total Sell Transactions |
1 |
2 |
5 |
35 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Grainger David J |
Chief Innovation Officer |
• – – |
2022-10-03 |
4 |
S |
$3.95 |
$11,270 |
D/D |
(2,853) |
908,575 |
|
- |
|
| Bush Tia L |
Chief Quality Officer |
• – – |
2022-10-03 |
4 |
S |
$3.95 |
$10,251 |
D/D |
(2,595) |
135,287 |
|
- |
|
| Bush Tia L |
Chief Quality Officer |
• – – |
2022-09-30 |
4 |
D |
$4.25 |
$24,501 |
D/D |
(5,765) |
134,235 |
|
- |
|
| Templeman Thomas |
Chief Technology Officer |
• – – |
2022-09-30 |
4 |
D |
$4.25 |
$22,874 |
D/D |
(5,382) |
134,868 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2022-09-30 |
4 |
D |
$4.25 |
$32,861 |
D/D |
(7,732) |
782,019 |
|
- |
|
| Weinhoff Gregory M |
Chief Financial Officer |
• – – |
2022-09-30 |
4 |
D |
$4.25 |
$47,949 |
D/D |
(11,282) |
228,718 |
|
- |
|
| Grainger David J |
Chief Innovation Officer |
• – – |
2022-09-30 |
4 |
D |
$4.25 |
$30,405 |
D/D |
(7,154) |
906,602 |
|
- |
|
| Chao David M |
Chief Administrative Officer |
• – – |
2022-09-30 |
4 |
D |
$4.25 |
$39,147 |
D/D |
(9,211) |
221,289 |
|
- |
|
| Hussain Iqbal J |
General Counsel |
• – – |
2022-09-30 |
4 |
D |
$4.25 |
$48,641 |
D/D |
(11,445) |
151,555 |
|
- |
|
| Templeman Thomas |
Chief Technology Officer |
• – – |
2022-09-30 |
4 |
S |
$4.07 |
$8,147 |
D/D |
(2,003) |
138,247 |
|
- |
|
| Weinhoff Gregory M |
Chief Financial Officer |
• – – |
2022-09-30 |
4 |
S |
$4.07 |
$16,270 |
D/D |
(4,000) |
236,000 |
|
- |
|
| Hussain Iqbal J |
General Counsel |
• – – |
2022-09-30 |
4 |
S |
$4.07 |
$15,151 |
D/D |
(3,725) |
159,275 |
|
- |
|
| Shahidi Javad |
Chief Medical Officer |
• – – |
2022-09-30 |
4 |
S |
$4.07 |
$11,092 |
D/D |
(2,727) |
162,273 |
|
- |
|
| Chao David M |
Chief Administrative Officer |
• – – |
2022-09-30 |
4 |
S |
$4.07 |
$13,833 |
D/D |
(3,401) |
227,099 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2022-09-30 |
4 |
S |
$4.07 |
$10,038 |
D/D |
(2,468) |
787,283 |
|
- |
|
| Grainger David J |
Chief Innovation Officer |
• – – |
2022-09-30 |
4 |
S |
$4.07 |
$9,469 |
D/D |
(2,328) |
911,428 |
|
- |
|
| Bush Tia L |
Chief Quality Officer |
• – – |
2022-09-30 |
4 |
S |
$4.07 |
$8,615 |
D/D |
(2,118) |
137,882 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2022-09-01 |
4 |
AS |
$4.41 |
$45,987 |
D/D |
(10,423) |
789,751 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2022-08-01 |
4 |
AS |
$4.45 |
$46,405 |
D/D |
(10,423) |
800,174 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2022-07-18 |
4 |
AS |
$4.87 |
$97,312 |
D/D |
(20,000) |
810,597 |
|
- |
|
| Weinhoff Gregory M |
Chief Financial Officer |
• – – |
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
230,000 |
240,000 |
|
- |
|
| Hussain Iqbal J |
General Counsel |
• – – |
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
160,000 |
163,000 |
|
- |
|
| Shahidi Javad |
Chief Medical Officer |
• – – |
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
165,000 |
165,000 |
|
- |
|
| Templeman Thomas |
Chief Technology Officer |
• – – |
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
140,000 |
140,250 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
830,597 |
|
- |
|
147 Records found
|
|
Page 4 of 6 |
|
|
